These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 26225229)

  • 1. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis.
    Sahota T; Berges A; Barton S; Cookson L; Zamuner S; Richards D
    CPT Pharmacometrics Syst Pharmacol; 2015 Feb; 4(2):e15. PubMed ID: 26225229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    Richards DB; Cookson LM; Berges AC; Barton SV; Lane T; Ritter JM; Fontana M; Moon JC; Pinzani M; Gillmore JD; Hawkins PN; Pepys MB
    N Engl J Med; 2015 Sep; 373(12):1106-14. PubMed ID: 26176329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
    Richards DB; Cookson LM; Barton SV; Liefaard L; Lane T; Hutt DF; Ritter JM; Fontana M; Moon JC; Gillmore JD; Wechalekar A; Hawkins PN; Pepys MB
    Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
    Gillmore JD; Tennent GA; Hutchinson WL; Gallimore JR; Lachmann HJ; Goodman HJ; Offer M; Millar DJ; Petrie A; Hawkins PN; Pepys MB
    Br J Haematol; 2010 Mar; 148(5):760-7. PubMed ID: 20064157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.
    Al-Shawi R; Tennent GA; Millar DJ; Richard-Londt A; Brandner S; Werring DJ; Simons JP; Pepys MB
    Open Biol; 2016 Feb; 6(2):150202. PubMed ID: 26842068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).
    Kolstoe SE; Jenvey MC; Purvis A; Light ME; Thompson D; Hughes P; Pepys MB; Wood SP
    Acta Crystallogr D Biol Crystallogr; 2014 Aug; 70(Pt 8):2232-40. PubMed ID: 25084341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
    Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
    Bodin K; Ellmerich S; Kahan MC; Tennent GA; Loesch A; Gilbertson JA; Hutchinson WL; Mangione PP; Gallimore JR; Millar DJ; Minogue S; Dhillon AP; Taylor GW; Bradwell AR; Petrie A; Gillmore JD; Bellotti V; Botto M; Hawkins PN; Pepys MB
    Nature; 2010 Nov; 468(7320):93-7. PubMed ID: 20962779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug targets for amyloidosis.
    Kolstoe SE; Wood SP
    Biochem Soc Trans; 2010 Apr; 38(2):466-70. PubMed ID: 20298204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
    Jager PL; Hazenberg BP; Franssen EJ; Limburg PC; van Rijswijk MH; Piers DA
    J Nucl Med; 1998 Apr; 39(4):699-706. PubMed ID: 9544684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.
    Kolstoe SE; Ridha BH; Bellotti V; Wang N; Robinson CV; Crutch SJ; Keir G; Kukkastenvehmas R; Gallimore JR; Hutchinson WL; Hawkins PN; Wood SP; Rossor MN; Pepys MB
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7619-23. PubMed ID: 19372378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoradiometric assay for human serum amyloid P component.
    Millar DJ; Hutchinson WL; Pepys MB
    J Immunol Methods; 2011 Aug; 371(1-2):18-24. PubMed ID: 21708157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.
    Hawkins PN; Lavender JP; Pepys MB
    N Engl J Med; 1990 Aug; 323(8):508-13. PubMed ID: 2377176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
    Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
    Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.
    Hawkins PN; Wootton R; Pepys MB
    J Clin Invest; 1990 Dec; 86(6):1862-9. PubMed ID: 2254450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
    Richards D; Millns H; Cookson L; Lukas MA
    Orphanet J Rare Dis; 2022 Jul; 17(1):259. PubMed ID: 35810311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits.
    Baltz ML; Caspi D; Evans DJ; Rowe IF; Hind CR; Pepys MB
    Clin Exp Immunol; 1986 Dec; 66(3):691-700. PubMed ID: 3568456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen.
    Noursadeghi M; Bickerstaff MC; Gallimore JR; Herbert J; Cohen J; Pepys MB
    Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14584-9. PubMed ID: 11121061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract.
    Shah PL; Gillmore JD; Copley SJ; Collins JV; Wells AU; du Bois RM; Hawkins PN; Nicholson AG
    Sarcoidosis Vasc Diffuse Lung Dis; 2002 Jun; 19(2):134-42. PubMed ID: 12102609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis.
    Hazenberg BP; van Rijswijk MH; Lub-de Hooge MN; Vellenga E; Haagsma EB; Posthumus MD; Jager PL
    J Nucl Med; 2007 Jun; 48(6):865-72. PubMed ID: 17504868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.